drugset
drugset / Trial / NCT04818723

Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Syndrome

NCT04818723 ↗

Completed 106 enrolled Nishtar Medical University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The investigators planned this research to elucidate if there is any efficacy of montelukast, a leukotriene receptor antagonist, in steroid sensitive childhood onset NS to help prevent relapses. This study was done to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)

Timeline

Start
2019-02-01
Primary completion
2020-05-30
Completion
2020-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 5 mg —

Indications

idiopathic nephrotic syndrome